Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Cosmographics Pvt. Ltd Signed LOI to Acquire All the Interest of AT-GC Biopharm

Abstract:
Avanti Therapeutics, Inc. announced that Cosmographics Pvt. Ltd (CPL) has signed a letter of intent to acquire 100% of the interest of its manufacturing operation subsidiary, AT-GC BioPharm, a biopharmaceutical manufacturing company headquartered in Baltimore, Maryland.

Cosmographics Pvt. Ltd Signed LOI to Acquire All the Interest of AT-GC Biopharm

Baltimore, MD. And Mumbai, India | Posted on November 3rd, 2007

Avanti Therapeutics, Inc. announced that Cosmographics Pvt. Ltd (CPL) has signed a letter of intent to acquire 100% of the interest of its manufacturing operation subsidiary, AT-GC BioPharm, a biopharmaceutical manufacturing company headquartered in Baltimore, Maryland. The company believes that the acquisition will expand CPL's presence in the biopharmaceutical manufacturing capacity by utilizing AT-GC BioPharm's well established intelligent manufacturing platform licenses and logistic facilities. The acquisition would also add direct outsourcing channels into small and mid sized biopharmaceutical companies in the region.

According to the letter of intent, CPL would use its internal available resource to complete the acquisition. "We are very happy to see this acquisition could take place," said Sunil Majmundar, CEO of Cosmographics Pvt. Ltd. "It would significantly improve our current manufacturing platforms and widen our product lines in the near future."

"The acquisition will help us develop new nanotechnology based technology platforms to accelerate our current drug development pipeline for cancer and infectious diseases" according to Dr. Arkesh Mehta, CEO of Avanti Therapeutics. Dr. Tracy Tucker, Director of R&D at Avanti Therapeutics is optimistic that the transaction will help in developing silica based nanoparticles with core-shell architecture that will be used to accelerate biomarker monitoring and targeted drug delivery of therapeutics.

####

About Avanti Therapeutics, Inc.
AT-GC BioPharm is an emerging biopharmaceutical company dedicated to the discovery and development of innovative technologies for rapidly advancing knowledge based manufacturing of biopharmaceutical products for consistent quality. AT-GC BioPharm is uniquely able to develop innovative technologies by accelerating and enhancing the process development skills and experience of proven drug manufacturing processes with world-class, proprietary process development technologies developed in collaboration with their partners. AT-GC BioPharm has established an exclusive worldwide strategic alliance with Avanti Therapeutics to develop and commercialize novel drug compounds for the treatment of infectious diseases and cancer. The company operates globally with headquarters in Clarksburg, Maryland, USA, and major offices in Baltimore, MD., Oxford, UK, and Mumbai, India. To learn why more and more biopharmaceutical companies trust AT-GC BioPharm as their preferred process development partner, visit http://www.at-gc.com .

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

For more information, please click here

Contacts:
Avanti Therapeutics
Attn.: Jenny Smith
Tel: +1 (301) 540-5474


Cosmographics, Pvt. Ltd.
Attn: S Majmundar
Tel: 91 2516-9310 and
91, 9820763136


Jenny Smith
Avanti Therapeutics, Inc.
+1-301-540-5474

Copyright © 2007 PR-USA.net

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

These microscopic fish are 3-D-printed to do more than swim: Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities August 26th, 2015

Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015

Cervical cancer detection goes portable August 25th, 2015

Antibacterial Nanocomposite Prevents Transmission of Infectious Diseases August 24th, 2015

Announcements

CWRU researchers efficiently charge a lithium-ion battery with solar cell: Coupling with perovskite solar cell holds potential for cleaner cars and more August 27th, 2015

Successful boron-doping of graphene nanoribbon August 27th, 2015

Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015

National Space Society Welcomes Janet Ivey As New NSS Governor: Janet Ivey of Janet's Planet is NOW IN ORBIT as a member of the Board of Governors of the National Space Society August 27th, 2015

Acquisitions/Mergers/Splits

GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy June 3rd, 2015

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

Keysight Technologies Begins Trading as Independent Company November 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic